The Food and Drug Administration (FDA) has granted emergency approval to the Novavax vaccine, which is distinct from the Pfizer and Moderna vaccines in that it does not use mRNA technology. Federal health officials hope that some Americans who remain unvaccinated—about 22 percent of all people in the U.S.—will be more comfortable opting for the Novavax vaccine.
The Novavax vaccine will also be a strong option for vaccinated but unboosted Americans. According to The New York Times, the side effects of the Novavax vaccine appear to be milder than the other vaccines, which produce aches and fatigue in many people.
